Braveheart, Attovia join next wave of biotech IPOs

An article from

IPO window

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

Published July 15, 2026

Getty Images

Braveheart, Attovia join next wave of biotech IPOs

Other newsrooms on this story

Related reading

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

Other newsrooms on this story

Related reading

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

I&I startup Attovia files to go public as biotech listings momentum builds

Kardigan extends biotech’s streak of big IPOs with $400M haul

‘The window’s open’: At BIO, investors take stock of a growing class of biotech…

Post-Hoc Live: What’s making biotech IPOs work again?

Parabilis sets a record with a $670M biotech IPO